INSMED INCORPORATED
At today's price, INSMED INCORPORATED (INSM) is priced for today's economics sustained for ~17.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Insmed is a commercial-stage biopharma whose value just shifted from one drug to two: ARIKAYCE for a rare lung infection and BRINSUPRI, the first and only approved treatment for non-cystic-fibrosis bronchiectasis, now launching. • The company is not yet profitable and is valued on its sales, about 31 times revenue, so the price assumes BRINSUPRI becomes a large, durable franchise rather than a hopeful launch. • Watch the BRINSUPRI launch trajectory and the ENCORE trial; BRINSUPRI booked $28.1
Is INSM overvalued? See what's priced in →
648 institutional managers reported holding INSM in 13F filings for the quarter ended 2026-03-31. Together they hold about 89% of the company; the top 10 hold 48%. 85 opened new positions that quarter. Held by Vanguard Group, BlackRock, FMR (Fidelity), among others. On the short side, 18.6M shares were sold short as of the 2026-06-15 count, about 9% of shares outstanding (4.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
INSM's share count grew 96.6% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at INSM over the trailing three years: 2025: 2 buys totaling $202k. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
INSM's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +1.0% | +11.1% |
| 2023-10-27 | -6.2% | +29.8% |
| 2024-02-23 | -3.4% | -9.1% |
| 2024-05-10 | -0.1% | +195.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
INSM's latest 8-K filings: 2026-07-16 (items 7.01, 9.01); 2026-05-15 (items 5.07); 2026-05-07 (items 2.02, 9.01); 2026-04-07 (items 7.01, 8.01, 9.01); 2026-03-23 (items 7.01, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.